Introduction: Nanosuspensions combine the advantages of nanotherapeutics (eg increased
dissolution rate and saturation solubility) with ease of commercialisation. Transformation of …

For oral drugs, the formulator and discovery chemist have a tool available to them that can
be used to navigate the risks associated with the selection and development of immediate …

In vitro dissolution testing is routinely used in the development of pharmaceutical products.
Whilst the dissolution testing methods are well established and standardized for oral dosage …

Inhalation is the preferred route for the treatment of lung diseases. More recently, also
formulations for systemic treatment have been developed. For efficient development of …

Orally inhaled products (OIPs) are gaining increased attention, as pulmonary delivery is a
preferred route for the treatment of various diseases. Yet, the field of inhalation …

In vitro-in vivo correlation is the establishment of a predictive relationship between in vitro
and in vivo data. In the context of cascade impactor results of orally inhaled pharmaceutical …

Cancer-targeting nanotherapeutics offer promising opportunities for selective delivery of
cytotoxic chemotherapeutics to cancer cells. However, the understanding of dissolution …

Dry powder inhalers (DPIs) are regularly used to treat respiratory diseases. Adding extrinsic
fine excipient particles to the blend of active pharmaceutical ingredient (API) and carrier is …

The bioaerogel microparticles have been recently developed for respiratory drug delivery
and attract fast increasing interests. These highly porous microparticles have ultralow …

Terbinafine is a broad-spectrum antifungal agent with potential therapeutic value in
management of pulmonary aspergillosis. To this end, dry powder inhalation formulations of …